Clinical trials: Head Neck Cancer Squamous Cell Recurrent
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00732745
- Testing
- docetaxel, oxaliplatin, vandetanib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma (ESCC)
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or…
- Trial name
- NCT07481058
- Testing
- KC1036, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
The purpose of this study is to find out if the combination of two established anti-cancer therapies are beneficial in participants with Head and Neck Squamous Cell Carcinoma (HNSCC).
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT03370276
- Testing
- Nivolumab, Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma HNSCC
- Trial name
- NCT07659678
- Testing
- 64Cu-DOTA-ECL1i
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Neoplasms
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts.
- Trial name
- NCT04958239
- Testing
- BI 765179, Ezabenlimab, Pembrolizumab
- Where
- 48 sites in United States, Australia and 13 more
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer
Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Inserting the gene for p53 into a person's tumor may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
- Trial name
- NCT00003257
- Testing
- Ad5CMV-p53 gene
- Where
- 10 sites in United States
- Volunteers
- 39 people
- Sponsor
- Aventis Pharmaceuticals
Squamous Cell Carcinoma of the Oral Cavity
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant…
- Trial name
- NCT02873819
- Testing
- GL-0817, Hiltonol, Sargramostim
- Where
- 33 sites in United States, Hungary and 5 more
- Volunteers
- 80 people
- Sponsor
- Gliknik Inc.
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer
The purpose of this study is to explore the use of a treatment called interstitial brachytherapy for patients who have a high risk resectable (able to be treated with surgery) recurrent head and neck cancer.
- Trial name
- NCT02794675
- Testing
- Cesium 131
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Case Comprehensive Cancer Center
Squamous Cell Carcinoma of the Head and Neck
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
In this Phase II trial of personalized immunotherapy in R/M HNSCC, gene expression of LAG3 and CTLA4 by RNA seq will be determined to select the appropriate agent (Ipilimumab or Relatlimab) to add to Nivolumab in patients with…
- Trial name
- NCT04326257
- Testing
- Nivolumab+Relatlimab, Nivolumab+Ipilimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dan Zandberg
Esophageal Squamous Cell Carcinoma (ESCC)
Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
This is a multicenter, retrospective observational study using existing medical records of patients with esophageal squamous cell carcinoma who received at least two cycles of neoadjuvant immunochemotherapy followed by curative…
- Trial name
- NCT07705412
- Testing
- Postoperative Radiotherapy, Lymph Node Dissection
- Where
- China
- Volunteers
- 465 people
- Sponsor
- Tongji Hospital
NPC, HNSCC
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R/M HNSCC/NPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.
- Conditions
- NPC, HNSCC, Recurrence, Metastasis
- Trial name
- NCT06719479
- Testing
- IAE0972+ Methotrexate, IAE0972+Docetaxel, IAE0972+Gemcitabine
- Volunteers
- 60 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Head and Neck Cancer
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
- Trial name
- CheckMate 651 (NCT02741570)
- Testing
- Nivolumab, Ipilimumab, Cetuximab/Erbitux
- Where
- 133 sites in United States, Australia and 16 more
- Volunteers
- 947 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Neoplasms
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell…
- Trial name
- NCT01087970
- Testing
- Pemetrexed, Cetuximab, Carboplatin
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Squamous Cell of Head and Neck
CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer
The aim of the study is to evaluate the efficacy of CetuGEX™ for the treatment of patients with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in combination with platinum-based chemotherapy) in…
- Trial name
- RESGEX (NCT02052960)
- Testing
- CetuGEX™, Cetuximab, Chemotherapy
- Where
- 34 sites in Belgium, France and 5 more
- Volunteers
- 240 people
- Sponsor
- Glycotope GmbH
Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck.
- Conditions
- Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT00084682
- Testing
- romidepsin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Oral Squamous Cell Carcinoma
Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell Carcinoma
Controversy over surgical treatment of clinically negative neck in early stage oral squamous cell carcinoma revolves around the uncertainty of its impact on patient prognosis.
- Trial name
- NCT01334320
- Testing
- elective neck dissection
- Where
- 4 sites in China
- Volunteers
- 448 people
- Sponsor
- Sun Yat-sen University
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk
The purpose of this study is to determine the treatment outcome of postoperative concurrent chemoradiation for head and neck squamous cell carcinoma with multiple minor risks.
- Trial name
- NCT00937612
- Testing
- Radiotherapy
- Where
- 3 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Chang Gung Memorial Hospital
Head and Neck Cancer
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line…
- Trial name
- NCT03358472
- Testing
- Pembrolizumab, Epacadostat, Cetuximab
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 89 people
- Sponsor
- Incyte Corporation
Recurrent Head and Neck Cancer, Head and Neck Cancer
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer.
- Conditions
- Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
- Trial name
- NCT03691714
- Testing
- Durvalumab, Cetuximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Cincinnati
Lymphoma, Metastatic Malignant Solid Neoplasm
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer
- Trial name
- NCT03229278
- Testing
- Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey